Wealthspire Advisors (Maryland)’s Myriad Genetics MYGN Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-501	Closed	-$17K	–	1439
2019 Q1	$17K	Buy	501 +300	+149%	+$9.13K	﹤0.01%	1344
2018 Q4	$6K	Buy	201 +13	+7%	+$468	﹤0.01%	1669
2018 Q3	$9K	Hold	188	–	–	﹤0.01%	1566
2018 Q2	$7K	Hold	188	–	–	﹤0.01%	1670
2018 Q1	$6K	Hold	188	–	–	﹤0.01%	1748
2017 Q4	$6K	Buy	188 +175	+1,346%	+$5.9K	﹤0.01%	1780
2017 Q3	$0	Buy	+13	New	+$371	﹤0.01%	2387
2016 Q4	–	Sell	-345	Closed	-$7K	–	1812
2016 Q3	$7K	Hold	345	–	–	﹤0.01%	1329
2016 Q2	$11K	Hold	345	–	–	﹤0.01%	1187
2016 Q1	$13K	Hold	345	–	–	﹤0.01%	1123
2015 Q4	$15K	Buy	+345	New	+$14.6K	﹤0.01%	1071

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s MYGN Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 501 shares — an estimated $17K sold.

Wealthspire Advisors (Maryland) first reported a position in MYGN in Q4 2015 and held it in 11 quarters. The position peaked at $17K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Wealthspire Advisors (Maryland) reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 501 Myriad Genetics shares in Q2 2019, an estimated $17K.
Wealthspire Advisors (Maryland) first reported a position in Myriad Genetics in Q4 2015 and held it in 11 quarters.
Wealthspire Advisors (Maryland)'s Myriad Genetics position peaked at $17K in Q1 2019.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.